SCHEDULE: Squadron Entities Disclose Significant NextCure Stake

Squadron Master Fund LP and related entities have disclosed beneficial ownership of 6.5% of NextCure, Inc.'s common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have filed a Schedule 13G regarding NextCure, Inc.
• Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank each beneficially own 173,861 shares of NextCure, Inc. common stock, representing 6.5% of the class.
• Squadron Master Fund LP beneficially owns 154,021 shares, representing 5.8% of the class.
• The ownership percentages are based on 2,676,110 shares of common stock outstanding as of August 4, 2025, as reported by NextCure, Inc. on its Form 10-Q.
• All reporting persons disclaim beneficial ownership over the reported securities, and the filing is not an admission of beneficial ownership.
• The securities were not acquired and are not held for the purpose or effect of changing or influencing control of NextCure, Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant, passive institutional investment in NextCure, Inc., which can be viewed as a vote of confidence. However, it does not provide operational or financial performance data, leading to a moderately positive sentiment.

Positives

• Disclosure of a significant institutional investment in NextCure, Inc. by Squadron Master Fund LP and related entities.
• The investment is certified as passive, indicating no immediate intent to influence control of the issuer.

Risks

• Potential for future changes in the ownership structure or investment intent of the reporting persons, although currently certified as passive.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
• Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.

Industry Context

This filing indicates a significant institutional investor's interest in NextCure, Inc., a biotechnology company. Such investments are common in the biotech sector, where institutional backing can signal confidence in a company's pipeline or strategic direction.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.
• Company Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant, passive ownership stake by Squadron Master Fund LP and related entities in NextCure, Inc. While institutional investment can be a positive signal, the filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. It simply indicates a notable investor's position without suggesting any immediate catalysts for significant price movement based solely on this disclosure. Therefore, a 'hold' recommendation is appropriate, pending further analysis of NextCure's financial performance and strategic developments.

Keywords

NextCure Inc., NCURE, Squadron Master Fund LP, Squadron Capital Management LLC, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Equity Stake